Group 1 - The company, Zhuhai Runduo Pharmaceutical Co., Ltd., has received the approval notice for the listing application of hydrochlorothiazide as a chemical raw material drug from the National Medical Products Administration [1][2] - The drug hydrochlorothiazide is indicated for conditions such as edema, hypertension, central or renal diabetes insipidus, and nephrolithiasis [3] - The approval of this drug enhances the company's product portfolio and strengthens its full industry chain layout, positively impacting future operational performance [3] Group 2 - The application for the drug was submitted in April 2024, with the approval process involving additional research and documentation submitted in 2025 [2] - The approval is based on compliance with the relevant requirements of the Drug Administration Law of the People's Republic of China [1]

Group 1 - The company, Zhuhai Runduo Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the listing application of hydrochlorothiazide as a chemical raw material drug [1] - The approval enhances the company's product portfolio and improves its competitiveness in the market, which is expected to have a positive impact on future operating performance [1] - The drug is indicated for conditions such as edema, hypertension, central or renal diabetes insipidus, and kidney stones [1] Group 2 - The approval process included a supplementary research notification received in January 2025, with the company completing the required work and submitting documentation by May 2025, leading to the final approval in August 2025 [1] - The registration number for the drug is Y20240000290, and the notification number is 2025YS00718 [1]

Group 1 - The core point of the article is that Rundu Co., Ltd. has received approval from the National Medical Products Administration for the listing application of hydrochlorothiazide as a chemical raw material drug [2] Group 2 - The announcement was made on the evening of August 19, indicating a significant regulatory milestone for the company [2] - The approval is expected to enhance the company's product portfolio and market position in the pharmaceutical industry [2]

Core Viewpoint - Rundu Co., Ltd. has received approval from the National Medical Products Administration for the listing application of hydrochlorothiazide, which is expected to enhance the company's product portfolio and market competitiveness, positively impacting future operating performance [1]. Group 1 - The approval of hydrochlorothiazide is applicable for treating edema-related diseases, hypertension, central or renal diabetes insipidus, and nephrolithiasis [1]. - This approval enriches the company's product categories and improves its full industry chain layout [1]. - The development is anticipated to strengthen the company's market competitiveness [1].

Core Viewpoint - The company, Rundu Co., Ltd. (002923.SZ), has received approval from the National Medical Products Administration for the marketing application of hydrochlorothiazide, which enhances its product portfolio and strengthens its full industry chain layout [1]. Group 1 - The approved product, hydrochlorothiazide, is indicated for conditions such as edema, hypertension, central or nephrogenic diabetes insipidus, and kidney stones [1]. - The approval of hydrochlorothiazide contributes to the diversification of the company's product offerings [1]. - This development is part of the company's strategy to improve its comprehensive industry chain [1].

Group 1 - The company, Rundu Co., Ltd. (002923.SZ), has received approval from the National Medical Products Administration for the listing application of hydrochlorothiazide as a chemical raw material drug [1] - Hydrochlorothiazide is indicated for the treatment of edema, hypertension, central or renal diabetes insipidus, and nephrolithiasis [1]

Core Viewpoint - The company, Rundu Co., Ltd. (002923.SZ), has received approval from the National Medical Products Administration for the listing application of hydrochlorothiazide, indicating a significant advancement in its product portfolio [1] Company Summary - Rundu Co., Ltd. has recently announced the receipt of a marketing approval notification for hydrochlorothiazide, a chemical raw material drug [1] - Hydrochlorothiazide is indicated for the treatment of edema-related diseases, hypertension, central or renal diabetes insipidus, and kidney stones [1]

Core Viewpoint - The approval of hydrochlorothiazide as a chemical raw material drug by the National Medical Products Administration enhances the company's product portfolio and strengthens its market competitiveness, positively impacting future operating performance [1] Group 1 - The company received the approval notice for hydrochlorothiazide from the National Medical Products Administration [1] - The application for the domestic production of hydrochlorothiazide was submitted in April 2024 and accepted by the Center for Drug Evaluation [1] - The company completed supplementary research and submitted the required documentation by May 2025, leading to the approval in August 2025 [1] Group 2 - Hydrochlorothiazide is indicated for conditions such as edema, hypertension, central or nephrogenic diabetes insipidus, and nephrolithiasis [1] - The approval of this product enriches the company's product categories and improves its full industry chain layout [1] - The new product is expected to have a positive impact on the company's future operating performance [1]